Updates from our programs and the wider field.
Regulatory milestones, clinical trial updates, and selected publications relating to vasopressin V1a receptor biology and Azevan's clinical candidates.
Recent updates.
-
August 1, 2026
Military Health Systems Research Symposium
Neal Simon, Azevan's CEO, will present the Company's progress in developing vasopressin 1a receptor antagonists as a new treatment for mild traumatic brain injury.
-
March 1, 2026
Fragile X Syndrome Phase 2 trial to start in Q3 2026
A Department of Defense–funded Phase 2 trial of SRX246 in Fragile X Syndrome will start enrolling participants in Q3 2026, in collaboration with leading investigators at Rush University, University of Cincinnati Children's Hospital, and University of California–Davis. The study includes home visits to allow participation by individuals previously unable to participate in clinical trials. An orphan designation is in process for use in Fragile X Syndrome.
-
February 1, 2026
Biocom's Global Partnering & Investor Conference
Neal Simon spoke on targeting vasopressin V1a receptor as a treatment for neuropsychiatric symptoms in CNS disorders and for preventing the cellular damage and cognitive issues following traumatic brain injury. The presentation highlighted circuit modulation for behavioral issues and minimizing the secondary injury cascade in TBI.
-
October 1, 2025
Congressionally Directed Medical Research Program Grant Awarded for Fragile X Trial
Azevan received a CDMRP award to conduct a Phase 2 trial, "SRX246: A Potential Treatment for Aggression in Fragile X Syndrome," in anxious/highly aggressive young men with Fragile X Syndrome. The study will be headed by Dr. Michael Brownstein, Azevan's Sr. VP Drug Development, and conducted in collaboration with Drs. Elizabeth Berry-Kravis (Rush University), Craig Erickson (Cincinnati Children's Hospital), and David Hessl (Univ. of California–Davis). Recruiting is now underway.